Trial Profile
RITUXIMAB IN LIFE THREATENING THERAPY RESISTANT PROGRESSIVE INTERSTITIAL PNEUMONITIS
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 08 Jun 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Pneumonitis
- Focus Therapeutic Use
- Acronyms RITUX-IP
- 01 Jun 2023 Results (n=21) elucidating if imaging of CD20-positive cells in the lungs allows prediction of the response to anti-CD20 treatment published in the European Journal of Nuclear Medicine and Molecular Imaging
- 30 May 2018 Status changed from active, no longer recruiting to completed.
- 25 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2017.